Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction

B. Wängberg, G. Westberg, Ulf Tylen, L. E. Tisell, S. Jansson, O. Nilsson, V. Johansson, T. Scherstén, H. Ahlman

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Sixty-four consecutive patients with disseminated midgut carcinoids were treated during an 8-year period according to a single clinical protocol aimed at aggressive tumor reduction by surgery alone or with subsequent hepatic artery embulization. All patients had markedly elevated urinary 5- hydroxyindoleacetic acid (5-HIAA) levels (581 ± 79 μmol/24 h) and hormonal symptoms. Fourteen patients (22%) reached anatomic and biochemical cure by surgery alone. At follow-up, the mean 5-HIAA levels were still normal after 69.0 ± 6.2 months; two patients had died from unrelated causes. With the introduction of somatostatin receptor scintigraphy, subclinical disease was diagnosed in 7 of these 14 patients. Forty patients with bilobar hepatic disease underwent embolization in combination with octreotide. In this group, 5-HIAA levels were still reduced by 55% after 71 ± 11 months of follow-up, and the 5-year survival was 56%, estimated from the total death hazard function. After embolization, two subgroups could be identified with marked differences in their long-term response to treatment. Ten patients were not embolized owing to complicating diseases. The 5-year survival for the entire series was 58%. A significantly increased risk of cardiovascular deaths was seen, which underlines the importance of total survival analysis in a disease with multiple hormonal effects. It is concluded that an active surgical approach must be recommended to patients with the midgut carcinoid syndrome. In patients with bilobar hepatic disease, embolization combined with octreotide treatment markedly reduced the 5-HIAA excretion and suggested a prolonged 5-year survival.

Original languageEnglish (US)
Pages (from-to)892-899
Number of pages8
JournalWorld Journal of Surgery
Volume20
Issue number7
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Carcinoid Tumor
Survival
Hydroxyindoleacetic Acid
Neoplasms
Octreotide
Somatostatin Receptors
Liver
Hepatic Artery
Survival Analysis
Clinical Protocols
Radionuclide Imaging
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Wängberg, B., Westberg, G., Tylen, U., Tisell, L. E., Jansson, S., Nilsson, O., ... Ahlman, H. (1996). Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World Journal of Surgery, 20(7), 892-899. https://doi.org/10.1007/s002689900136

Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. / Wängberg, B.; Westberg, G.; Tylen, Ulf; Tisell, L. E.; Jansson, S.; Nilsson, O.; Johansson, V.; Scherstén, T.; Ahlman, H.

In: World Journal of Surgery, Vol. 20, No. 7, 1996, p. 892-899.

Research output: Contribution to journalArticle

Wängberg, B, Westberg, G, Tylen, U, Tisell, LE, Jansson, S, Nilsson, O, Johansson, V, Scherstén, T & Ahlman, H 1996, 'Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction', World Journal of Surgery, vol. 20, no. 7, pp. 892-899. https://doi.org/10.1007/s002689900136
Wängberg, B. ; Westberg, G. ; Tylen, Ulf ; Tisell, L. E. ; Jansson, S. ; Nilsson, O. ; Johansson, V. ; Scherstén, T. ; Ahlman, H. / Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. In: World Journal of Surgery. 1996 ; Vol. 20, No. 7. pp. 892-899.
@article{afa1b29f1a0d449da4b7aa99886d0ef2,
title = "Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction",
abstract = "Sixty-four consecutive patients with disseminated midgut carcinoids were treated during an 8-year period according to a single clinical protocol aimed at aggressive tumor reduction by surgery alone or with subsequent hepatic artery embulization. All patients had markedly elevated urinary 5- hydroxyindoleacetic acid (5-HIAA) levels (581 ± 79 μmol/24 h) and hormonal symptoms. Fourteen patients (22{\%}) reached anatomic and biochemical cure by surgery alone. At follow-up, the mean 5-HIAA levels were still normal after 69.0 ± 6.2 months; two patients had died from unrelated causes. With the introduction of somatostatin receptor scintigraphy, subclinical disease was diagnosed in 7 of these 14 patients. Forty patients with bilobar hepatic disease underwent embolization in combination with octreotide. In this group, 5-HIAA levels were still reduced by 55{\%} after 71 ± 11 months of follow-up, and the 5-year survival was 56{\%}, estimated from the total death hazard function. After embolization, two subgroups could be identified with marked differences in their long-term response to treatment. Ten patients were not embolized owing to complicating diseases. The 5-year survival for the entire series was 58{\%}. A significantly increased risk of cardiovascular deaths was seen, which underlines the importance of total survival analysis in a disease with multiple hormonal effects. It is concluded that an active surgical approach must be recommended to patients with the midgut carcinoid syndrome. In patients with bilobar hepatic disease, embolization combined with octreotide treatment markedly reduced the 5-HIAA excretion and suggested a prolonged 5-year survival.",
author = "B. W{\"a}ngberg and G. Westberg and Ulf Tylen and Tisell, {L. E.} and S. Jansson and O. Nilsson and V. Johansson and T. Scherst{\'e}n and H. Ahlman",
year = "1996",
doi = "10.1007/s002689900136",
language = "English (US)",
volume = "20",
pages = "892--899",
journal = "Presentations from the 9th Annual Electric Utilities Environmental Conference",
issn = "0364-2313",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction

AU - Wängberg, B.

AU - Westberg, G.

AU - Tylen, Ulf

AU - Tisell, L. E.

AU - Jansson, S.

AU - Nilsson, O.

AU - Johansson, V.

AU - Scherstén, T.

AU - Ahlman, H.

PY - 1996

Y1 - 1996

N2 - Sixty-four consecutive patients with disseminated midgut carcinoids were treated during an 8-year period according to a single clinical protocol aimed at aggressive tumor reduction by surgery alone or with subsequent hepatic artery embulization. All patients had markedly elevated urinary 5- hydroxyindoleacetic acid (5-HIAA) levels (581 ± 79 μmol/24 h) and hormonal symptoms. Fourteen patients (22%) reached anatomic and biochemical cure by surgery alone. At follow-up, the mean 5-HIAA levels were still normal after 69.0 ± 6.2 months; two patients had died from unrelated causes. With the introduction of somatostatin receptor scintigraphy, subclinical disease was diagnosed in 7 of these 14 patients. Forty patients with bilobar hepatic disease underwent embolization in combination with octreotide. In this group, 5-HIAA levels were still reduced by 55% after 71 ± 11 months of follow-up, and the 5-year survival was 56%, estimated from the total death hazard function. After embolization, two subgroups could be identified with marked differences in their long-term response to treatment. Ten patients were not embolized owing to complicating diseases. The 5-year survival for the entire series was 58%. A significantly increased risk of cardiovascular deaths was seen, which underlines the importance of total survival analysis in a disease with multiple hormonal effects. It is concluded that an active surgical approach must be recommended to patients with the midgut carcinoid syndrome. In patients with bilobar hepatic disease, embolization combined with octreotide treatment markedly reduced the 5-HIAA excretion and suggested a prolonged 5-year survival.

AB - Sixty-four consecutive patients with disseminated midgut carcinoids were treated during an 8-year period according to a single clinical protocol aimed at aggressive tumor reduction by surgery alone or with subsequent hepatic artery embulization. All patients had markedly elevated urinary 5- hydroxyindoleacetic acid (5-HIAA) levels (581 ± 79 μmol/24 h) and hormonal symptoms. Fourteen patients (22%) reached anatomic and biochemical cure by surgery alone. At follow-up, the mean 5-HIAA levels were still normal after 69.0 ± 6.2 months; two patients had died from unrelated causes. With the introduction of somatostatin receptor scintigraphy, subclinical disease was diagnosed in 7 of these 14 patients. Forty patients with bilobar hepatic disease underwent embolization in combination with octreotide. In this group, 5-HIAA levels were still reduced by 55% after 71 ± 11 months of follow-up, and the 5-year survival was 56%, estimated from the total death hazard function. After embolization, two subgroups could be identified with marked differences in their long-term response to treatment. Ten patients were not embolized owing to complicating diseases. The 5-year survival for the entire series was 58%. A significantly increased risk of cardiovascular deaths was seen, which underlines the importance of total survival analysis in a disease with multiple hormonal effects. It is concluded that an active surgical approach must be recommended to patients with the midgut carcinoid syndrome. In patients with bilobar hepatic disease, embolization combined with octreotide treatment markedly reduced the 5-HIAA excretion and suggested a prolonged 5-year survival.

UR - http://www.scopus.com/inward/record.url?scp=20244387404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244387404&partnerID=8YFLogxK

U2 - 10.1007/s002689900136

DO - 10.1007/s002689900136

M3 - Article

C2 - 8678968

AN - SCOPUS:20244387404

VL - 20

SP - 892

EP - 899

JO - Presentations from the 9th Annual Electric Utilities Environmental Conference

JF - Presentations from the 9th Annual Electric Utilities Environmental Conference

SN - 0364-2313

IS - 7

ER -